This article was originally published in Start Up
GenoPlex Inc. hopes to provide validated gene targets to Big Pharma. The company is focusing its gene-seeking efforts on aging, learning and memory, and the action of anesthetics and alcohol.
You may also be interested in...
By 1994, functional genomics companies began forming to help a Big Pharma suddenly deluged by genomic data. Through the study of model genetic systems like nematodes and fruit flies, or homogenous peoples, these gene hunters hope to gain an understanding of how and when genes function--under normal conditions and in disease.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.